{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenocarcinoma+of+the+Prostate+Stage+III&page=6", "query": { "condition": "Adenocarcinoma of the Prostate Stage III", "page": 6 }, "page_size": 10 }, "pagination": { "page": 6, "page_size": 10, "total_count": 181, "total_pages": 19, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenocarcinoma+of+the+Prostate+Stage+III&page=7&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenocarcinoma+of+the+Prostate+Stage+III&page=5&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T14:53:12.675Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00589472", "title": "Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Adenocarcinoma", "Stage I Prostate Cancer", "Stage IIA Prostate Cancer", "Stage IIB Prostate Cancer", "Stage III Prostate Cancer" ], "interventions": [ { "name": "Bicalutamide", "type": "DRUG" }, { "name": "Goserelin Acetate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Leuprolide Acetate", "type": "DRUG" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" }, { "name": "Vorinostat", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "MALE", "summary": "19 Years and older · Male only" }, "enrollment_count": 19, "start_date": "2007-11", "completion_date": "2010-06", "has_results": true, "last_update_posted_date": "2017-10-06", "last_synced_at": "2026-10-14T14:53:12.675Z", "location_count": 15, "location_summary": "Los Angeles, California • San Francisco, California • Chicago, Illinois + 12 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00589472" }, { "nct_id": "NCT00003045", "title": "Hyperthermia Plus Radiation Therapy in Treating Patients With Nonmetastatic Advanced Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Hyperthermia", "type": "DEVICE" }, { "name": "XRT", "type": "RADIATION" } ], "intervention_types": [ "DEVICE", "RADIATION" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 38, "start_date": "1997-04", "completion_date": "2003-12-31", "has_results": false, "last_update_posted_date": "2017-04-26", "last_synced_at": "2026-10-14T14:53:12.675Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003045" }, { "nct_id": "NCT03963739", "title": "Effect of Treatment on Work Experience in Patients With Stage I-III Prostate Cancer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Prostate Adenocarcinoma", "Stage I Prostate Cancer", "Stage II Prostate Cancer", "Stage III Prostate Cancer" ], "interventions": [ { "name": "Interview", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 255, "start_date": "2019-07-19", "completion_date": "2025-03-25", "has_results": false, "last_update_posted_date": "2025-07-16", "last_synced_at": "2026-10-14T14:53:12.675Z", "location_count": 325, "location_summary": "Phoenix, Arizona • Fort Smith, Arkansas • Hot Springs, Arkansas + 204 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Arroyo Grande", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03963739" }, { "nct_id": "NCT04455750", "title": "A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Castration-Resistant Prostate Carcinoma", "Metastatic Prostate Adenocarcinoma", "Stage IV Prostate Cancer AJCC v8", "Stage IVA Prostate Cancer AJCC v8", "Stage IVB Prostate Cancer AJCC v8" ], "interventions": [ { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Rucaparib camsylate", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Leuprolide Acetate", "type": "DRUG" }, { "name": "Goserelin Acetate", "type": "DRUG" }, { "name": "Degarelix", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 61, "start_date": "2021-10-14", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2026-02-05", "last_synced_at": "2026-10-14T14:53:12.675Z", "location_count": 414, "location_summary": "Anchorage, Alaska • Phoenix, Arizona • Hot Springs, Arkansas + 298 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT04455750" }, { "nct_id": "NCT03368547", "title": "68Ga-PSMA-11 PET/CT in Imaging Patients With Intermediate or High Risk Prostate Cancer Before Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Prostate Adenocarcinoma", "Stage IIB Prostate Cancer AJCC v7", "Stage III Prostate Cancer AJCC v7", "Stage IV Prostate Cancer AJCC v7" ], "interventions": [ { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Gallium Ga 68 Gozetotide", "type": "RADIATION" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "RADIATION" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "MALE", "summary": "Male only" }, "enrollment_count": 400, "start_date": "2016-12-12", "completion_date": "2021-06-18", "has_results": false, "last_update_posted_date": "2023-04-12", "last_synced_at": "2026-10-14T14:53:12.675Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03368547" }, { "nct_id": "NCT01409200", "title": "Antiandrogen Therapy With or Without Axitinib Before Surgery in Treating Patients With Previously Untreated Prostate Cancer With Known or Suspected Lymph Node Metastasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Malignant Neoplasm in Lymph Node", "Prostate Ductal Adenocarcinoma", "Stage III Prostate Adenocarcinoma AJCC v7", "Stage IV Prostate Adenocarcinoma AJCC v7" ], "interventions": [ { "name": "Antiandrogen Therapy", "type": "DRUG" }, { "name": "Axitinib", "type": "DRUG" }, { "name": "Radical Prostatectomy", "type": "PROCEDURE" }, { "name": "Regional Lymph Node Dissection", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 73, "start_date": "2012-03-26", "completion_date": "2026-02-05", "has_results": false, "last_update_posted_date": "2026-03-03", "last_synced_at": "2026-10-14T14:53:12.675Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01409200" }, { "nct_id": "NCT00089362", "title": "Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Male Breast Cancer", "Recurrent Adenoid Cystic Carcinoma of the Oral Cavity", "Recurrent Basal Cell Carcinoma of the Lip", "Recurrent Breast Cancer", "Recurrent Colon Cancer", "Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Recurrent Gastric Cancer", "Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Recurrent Lymphoepithelioma of the Nasopharynx", "Recurrent Lymphoepithelioma of the Oropharynx", "Recurrent Melanoma", "Recurrent Metastatic Squamous Neck Cancer With Occult Primary", "Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Recurrent Mucoepidermoid Carcinoma of the Oral Cavity", "Recurrent Ovarian Epithelial Cancer", "Recurrent Prostate Cancer", "Recurrent Renal Cell Cancer", "Recurrent Salivary Gland Cancer", "Recurrent Squamous Cell Carcinoma of the Hypopharynx", "Recurrent Squamous Cell Carcinoma of the Larynx", "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity", "Recurrent Squamous Cell Carcinoma of the Nasopharynx", "Recurrent Squamous Cell Carcinoma of the Oropharynx", "Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Recurrent Verrucous Carcinoma of the Larynx", "Recurrent Verrucous Carcinoma of the Oral Cavity", "Stage III Adenoid Cystic Carcinoma of the Oral Cavity", "Stage III Basal Cell Carcinoma of the Lip", "Stage III Colon Cancer", "Stage III Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Stage III Gastric Cancer", "Stage III Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Stage III Lymphoepithelioma of the Nasopharynx", "Stage III Lymphoepithelioma of the Oropharynx", "Stage III Melanoma", "Stage III Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Stage III Mucoepidermoid Carcinoma of the Oral Cavity", "Stage III Ovarian Epithelial Cancer", "Stage III Renal Cell Cancer", "Stage III Salivary Gland Cancer", "Stage III Squamous Cell Carcinoma of the Hypopharynx", "Stage III Squamous Cell Carcinoma of the Larynx", "Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage III Squamous Cell Carcinoma of the Nasopharynx", "Stage III Squamous Cell Carcinoma of the Oropharynx", "Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage III Verrucous Carcinoma of the Larynx", "Stage III Verrucous Carcinoma of the Oral Cavity", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer", "Stage IV Adenoid Cystic Carcinoma of the Oral Cavity", "Stage IV Basal Cell Carcinoma of the Lip", "Stage IV Breast Cancer", "Stage IV Colon Cancer", "Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Stage IV Gastric Cancer", "Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Stage IV Lymphoepithelioma of the Nasopharynx", "Stage IV Lymphoepithelioma of the Oropharynx", "Stage IV Melanoma", "Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Stage IV Mucoepidermoid Carcinoma of the Oral Cavity", "Stage IV Ovarian Epithelial Cancer", "Stage IV Prostate Cancer", "Stage IV Renal Cell Cancer", "Stage IV Salivary Gland Cancer", "Stage IV Squamous Cell Carcinoma of the Hypopharynx", "Stage IV Squamous Cell Carcinoma of the Larynx", "Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IV Squamous Cell Carcinoma of the Nasopharynx", "Stage IV Squamous Cell Carcinoma of the Oropharynx", "Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage IV Verrucous Carcinoma of the Larynx", "Stage IV Verrucous Carcinoma of the Oral Cavity", "Unspecified Adult Solid Tumor, Protocol Specific", "Untreated Metastatic Squamous Neck Cancer With Occult Primary" ], "interventions": [ { "name": "alvespimycin hydrochloride", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2004-07", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-04-10", "last_synced_at": "2026-10-14T14:53:12.675Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00089362" }, { "nct_id": "NCT03581500", "title": "Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Predicting Treatment Response in Patients With Prostate Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Adenocarcinoma", "PSA Level Greater Than Ten", "Stage IIB Prostate Cancer AJCC v8", "Stage III Prostate Cancer AJCC v8", "Stage IIIA Prostate Cancer AJCC v8", "Stage IIIB Prostate Cancer AJCC v8", "Stage IIIC Prostate Cancer AJCC v8", "Stage IV Prostate Cancer AJCC v8", "Stage IVA Prostate Cancer AJCC v8", "Stage IVB Prostate Cancer AJCC v8" ], "interventions": [ { "name": "Hyperpolarized Carbon C 13 Pyruvate", "type": "DRUG" }, { "name": "Magnetic Resonance Spectroscopic Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "MALE", "summary": "Male only" }, "enrollment_count": 0, "start_date": "2019-02-06", "completion_date": "2024-10-16", "has_results": false, "last_update_posted_date": "2025-04-23", "last_synced_at": "2026-10-14T14:53:12.675Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03581500" }, { "nct_id": "NCT00024167", "title": "Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Docetaxel", "type": "DRUG" }, { "name": "Doxorubicin hydrochloride", "type": "DRUG" }, { "name": "Estramustine phosphate sodium", "type": "DRUG" }, { "name": "Ketoconazole", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Vinblastine", "type": "DRUG" }, { "name": "Strontium chloride Sr 89", "type": "RADIATION" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 265, "start_date": "2002-04", "completion_date": null, "has_results": true, "last_update_posted_date": "2016-03-22", "last_synced_at": "2026-10-14T14:53:12.675Z", "location_count": 40, "location_summary": "Gainesville, Georgia • Savannah, Georgia • Hines, Illinois + 23 more", "locations": [ { "city": "Gainesville", "state": "Georgia" }, { "city": "Savannah", "state": "Georgia" }, { "city": "Hines", "state": "Illinois" }, { "city": "Rockford", "state": "Illinois" }, { "city": "Bettendorf", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT00024167" }, { "nct_id": "NCT02472275", "title": "PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Stage I Prostate Adenocarcinoma", "Stage II Prostate Adenocarcinoma", "Stage III Prostate Adenocarcinoma" ], "interventions": [ { "name": "Antiandrogen Therapy", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Multitargeted Tyrosine Kinase Inhibitor PLX3397", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "OTHER", "RADIATION" ], "sponsor": "Barbara Ann Karmanos Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 8, "start_date": "2015-06", "completion_date": "2019-08-05", "has_results": false, "last_update_posted_date": "2020-10-06", "last_synced_at": "2026-10-14T14:53:12.675Z", "location_count": 3, "location_summary": "Detroit, Michigan • Petoskey, Michigan", "locations": [ { "city": "Detroit", "state": "Michigan" }, { "city": "Petoskey", "state": "Michigan" }, { "city": "Petoskey", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02472275" } ] }